Business Context and Reporting Period
Company: MacroGenics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 22, 2014
Event Date: December 19, 2014
MacroGenics, Inc. entered into a strategic transaction with Janssen Biotech, Inc. ("Janssen") and its affiliate, Johnson & Johnson Innovation – JJDC, Inc. ("JJDC"). The transaction consists of a Collaboration Agreement with Janssen and a Stock Purchase Agreement with JJDC. Closing is subject to regulatory waiting periods and customary conditions.
Key Financial Metrics and Transaction Terms
This filing details a material definitive agreement rather than periodic financial results. Key financial terms include:
- Upfront License Fee: $50 million payable by Janssen to MacroGenics.
- Equity Investment: $75 million investment by JJDC for 1,923,077 new shares of common stock at $39.00 per share.
- Potential Milestones: Up to $575 million in clinical, regulatory, and commercialization milestone payments contingent on success.
- Royalties: Double-digit royalties on global net sales.
- Profit Share Option: MacroGenics may fund clinical development to receive a share of net profits in the U.S. and Canada in lieu of certain milestones and royalties.
Note: The filing does not provide current revenue, profit, cash flow, or debt figures for the company.
Material Changes and Product Focus
The primary material change is the partnership to develop MGD011, a proprietary product candidate utilizing MacroGenics' Dual-Affinity Re-Targeting (DART®) platform.
- Product: MGD011 targets CD19 (on B cells) and CD3 (on T cells) for the treatment of leukemias and lymphomas.
- Development Stage: Pre-clinical development.
- Responsibilities: Janssen assumes full responsibility for development following the submission of the investigational new drug application (IND) to the FDA.
- Commercialization: Janssen is obligated to use commercially reasonable efforts for development, regulatory, and commercialization activities. MacroGenics has the option to co-promote in the U.S.
Guidance, Risks, and Contingencies
Termination Rights:
- Janssen may terminate the Collaboration Agreement with 180 days' written notice.
- Termination is permitted by Janssen in cases of safety concerns or MacroGenics' bankruptcy.
- MacroGenics may terminate if Janssen challenges certain patents.
- Customary breach provisions apply for both parties.
Investor Rights (JJDC):
- JJDC shares are exempt from registration under Section 4(a)(2) of the 1933 Act.
- JJDC agreed to hold shares for a specified period and vote in accordance with the Board's recommendations (excluding extraordinary transactions).
- JJDC provided an irrevocable proxy for certain matters.
- JJDC agreed to a standstill regarding the acquisition of additional equity interests for a certain period.
Investor Verification Checklist
- Verify the closing of the transaction and receipt of the $50 million upfront fee and $75 million equity investment.
- Monitor the submission of the investigational new drug application (IND) for MGD011, which triggers Janssen's full development responsibility.
- Review the full text of the Collaboration and Stock Purchase Agreements filed as exhibits to the Form 10-K for detailed milestone definitions and termination clauses.
- Assess the impact of the 1,923,077 new shares on existing shareholder dilution.
- Track the status of Hart-Scott-Rodino Act waiting periods and other closing conditions.